All In Biotech

Drug Trial Radar · NCT01458119

Open-Label Phase 3 Long-Term Safety Study of Migalastat

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease

Last checked: Nov 19, 2026Latest source record: Oct 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

85

Actual

Start

Oct 14, 2011

Primary completion

Feb 17, 2016

Study completion Feb 17, 2016

Sponsor

Lead sponsor
Amicus TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 24, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a long-term, open-label study of migalastat (123 milligrams \[mg\] of migalastat \[equivalent to 150 mg of migalastat hydrochloride\]) (migalastat) in participants with Fabry disease who completed treatment in a previous monotherapy trial with migalastat.

Conditions

  • Fabry Disease

Interventions

  • migalastat hydrochlorideDrug

    Oral capsule QOD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline to End of Follow-up (30 days after the end of this 42-month study), with AE reporting occurring at each study visit, which occurred once every 6 months.

Locations

25 sites in 13 countries. Site status is shown where the registry gives one.

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Kansas City, Kansas

  • Site not named

    Boston, Massachusetts

  • Site not named

    Grand Rapids, Michigan

  • Site not named

    New York, New York

  • Site not named

    Portland, Oregon

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Dallas, Texas

  • Site not named

    Fairfax, Virginia

  • Site not named

    Seattle, Washington

  • Site not named

    Pilar, Argentina

  • Site not named

    Adelaide, Australia

  • Site not named

    Parkville, Australia

  • Site not named

    Edegem, Belgium

  • Site not named

    Porto Alegre, Brazil

  • Site not named

    Montreal, Canada

  • Site not named

    Copenhagen, Denmark

  • Site not named

    Cairo, Egypt

  • Site not named

    Garches, France

  • Site not named

    Roma, Italy

  • Site not named

    Barcelona, Spain

  • Site not named

    Ankara, Turkey (Türkiye)

  • Site not named

    London, United Kingdom

  • Site not named

    Salford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.